Cover Image
Market Research Report

Erythropoietin Market in Japan 2015-2019

Published by TechNavio (Infiniti Research Ltd.) Product code 239356
Published Content info 65 Pages
Immediate Delivery Available
Price
Back to Top
Erythropoietin Market in Japan 2015-2019
Published: September 9, 2015 Content info: 65 Pages
Description

About erythropoietin

Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an excess of erythropoietin to maintain a normal level of red blood cells. When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs). These agents are similar to natural erythropoietin in structure and function. They can be produced by recombinant DNA technology and are used in the treatment of anemia resulting from renal disease, cancer, HIV, injuries, or neurological conditions.

Technavio's analysts forecast the erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the erythropoietin market in Japan for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.

Technavio's report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key vendors

  • Chugai Pharmaceutical
  • JCR Pharmaceuticals
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin

Other Prominent Vendors

  • Eisai
  • Otsuka
  • Taiho Pharmaceutical
  • Takeda

Market driver

  • Increased incidence of anemia due to illness
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Table of Contents
Product Code: IRTNTR7268

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Biosimilars and biologics industry

  • Overview
  • Emerging role of biosimilars
  • Factors influencing biosimilars and biologics industry
  • Biosimilars: Business and pricing strategy
  • Biosimilars industry: Viewpoints of providers, payers, buyers, vendors, and regulatory bodies

PART 06: Japan: Country snapshot

  • Pharmaceutical industry in Japan
  • Biosimilars and biologics industry in Japan
  • Regulatory landscape
  • Healthcare reforms
  • Erythropoietin: Addressable market in Japan

PART 07: Global erythropoietin drugs market

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by application

  • End-stage renal disease
  • Cancer
  • HIV
  • Wounds and neural disease

PART 10: Market segmentation by product

  • First-generation erythropoietin formulation
  • Second-generation erythropoietin formulation
  • Biosimilars

PART 11: Market segmentation by end-user

  • Hospitals
  • Pharmacies

PART 12: Market drivers

  • Increased incidence of anemia
  • Reimbursement for erythropoietin preparations
  • Favorable growth opportunities

PART 13: Impact of drivers

PART 14: Market challenges

  • Complex manufacturing process
  • Complicated regulatory framework
  • Physician's reluctance to prescribe biosimilars

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Strategic alliances
  • Increased R&D of innovative molecule drugs
  • Focus on biosimilars

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014

PART 18: Key vendor analysis

  • Chugai Pharmaceutical
  • JCR Pharmaceuticals
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Definition of biosimilars by organizations
  • Exhibit 03: Factors influencing biosimilars and biologics industry
  • Exhibit 04: Patent expiries of branded biologics
  • Exhibit 05: Impact of biosimilar cost savings on various sectors
  • Exhibit 06: Factors affecting success of biosimilars
  • Exhibit 07: Biosimilars industry: Point-of-view
  • Exhibit 08: Revenue of pharmaceuticals in Japan 2013 and 2020 ($ billions)
  • Exhibit 09: Pharmaceutical R&D expenditure in Japan 2000-2012 ($ millions)
  • Exhibit 10: Japan's percentage share in world imports of pharmaceuticals 2013
  • Exhibit 11: Japan's percentage share in world exports of pharmaceutical 2013
  • Exhibit 12: Biosimilars approved by PMDA in Japan
  • Exhibit 13: Review process of biosimilars in Japan
  • Exhibit 14: Number of people with cancer in Japan 2010-2013
  • Exhibit 15: Incidence of cancers in Japan 2011
  • Exhibit 16: Approved erythropoietin biosimilars
  • Exhibit 17: Erythropoietin drugs market in Japan 2014-2019 ($ millions)
  • Exhibit 18: Five forces analysis
  • Exhibit 19: Erythropoietin drugs market in Japan by end-user 2014
  • Exhibit 20: Erythropoietin drugs market in Japan by product in hospitals 2014
  • Exhibit 21: Erythropoietin drugs market segmentation in Japan by product in retail pharmacies 2014
  • Exhibit 22: Number of people receiving dialysis in Japan 2008-2012
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: Kyowa Hakko Kirin: YoY growth and revenue of NESP 2010-2014 ($ millions)
  • Exhibit 26: Kyowa Hakko Kirin: YoY growth and revenue of ESPO/NESP 2010-2012 ($ millions)
  • Exhibit 27: Chugai Pharmaceutical: YoY growth and revenue of Epogin 2010-2014 ($ millions)
  • Exhibit 28: Chugai Pharmaceutical: YoY growth and revenue of Mircera 2011-2014 ($ millions)
  • Exhibit 29: JCR Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection JCR 2011-2014 ($ millions)
  • Exhibit 30: Kissei Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection (JCR) 2011-2014 ($ millions)
  • Exhibit 31: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
  • Exhibit 32: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 33: Kissei Pharmaceutical: Business segmentation by revenue 2015
  • Exhibit 34: Kissei Pharmaceutical: Business segmentation by revenue 2014 and 2015 ($ millions)
  • Exhibit 35: Kissei Pharmaceutical: Geographical segmentation by revenue 2015
  • Exhibit 36: Kyowa Hakko Kirin: Business segmentation by revenue 2014
  • Exhibit 37: Kyowa Hakko Kirin: Business segmentation by revenue 2013 and 2014
  • Exhibit 38: Kyowa Hakko Kirin: Geographical segmentation by revenue 2014
Back to Top